Merck’s Winrevair Cuts Clinical Worsening Risk By 76% Among Hypertension Patients

All NewsSeptember 30, 2025

Merck reported Phase 3 results showing Winrevair significantly reduced clinical worsening in pulmonary arterial hypertension patients.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent